U.S. FDA Approves IMBRUVICA® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved...

Related Keywords

,Craig Tendler ,Christie Corbett ,Susan Stewart ,Janssen Research ,Janssen Biotech Inc ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,Translational Sciences ,Diagnostics Medical Affairs ,Global Head Of Late Development ,National Comprehensive Cancer Network ,None Of The Janssen Pharmaceutical Companies ,National Center ,Drug Administration ,Exchange Commission ,Hematology Oncology Janssen Research Development ,Companies Of Johnson ,Johnson ,Seattle Children ,Executive Director ,Confidence Interval ,Global Head ,Slate Development ,Medical Affairs ,Oncology Janssen Research ,Janssen Biotech ,National Comprehensive Cancer ,Cardiac Failure ,Sudden Death ,Primary Malignancies ,Lysis Syndrome ,Fetal Toxicity ,B Cell Malignancies ,Hepatic Impairment ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Report ,Castles Smith ,Advancing Translational ,Chronic Graft Versus Host ,Accessed August ,Chronic Graft Vs ,Host Disease ,Adolescents With ,Present Status ,Personalised Management ,Clinical Practice Guidelines ,Chronic Lymphocytic ,Comprehensive Cancer ,The Janssen Pharmaceutical Companies Of Johnson Amp ,